Did you know?
ChinaBio® Group is an investment, consulting and media firm helping western life science companies achieve success in China. ChinaBio works with U.S., European and APAC companies seeking partnerships, acquisitions, novel technologies and funding in China.  

>> Learn more…

Site Search

>> Advanced Search

  Quick Search:
 
 

Free Newsletter

  Email address:
   

Simcere Obtains SFDA Approval for Rheumatoid Arthritis Treatment

publication date: Aug 25, 2011
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
Simcere Pharma was granted SFDA approval for Iremod, an oral iguratimod drug classified as belonging to the category of Disease Modifying Anti-rheumatic Drugs (DMARDS). It will be indicated to treat active rheumatoid arthritis. Iremod, which was developed by Simcere, will be the first global iguratimod offering. Simcere expected SFDA approval of the drug as long ago as 2009. However, the drug inhibits COX-2, which may have complicated the regulatory process. More details....

Stock Symbol: (NYSE: SCR)     Share this with colleagues:  

 


This article is available for purchase - please click here for details.


Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...

Login

  

    
   
Alibaba IPO
Event Updates
Greg Scott will be attending and speaking at these events:
 
 
 
Hope to see you there!
 
ChinaBio® Events
ChinaBio Leadership Retreat 2014
Suzhou, China
October 23-24, 2014
 
China Forum 2014

Frankfurt, Germany
November 2, 2014

>> More events...

Our Partners
Annual Sponsors
Official Partners
Supporting Partners
Media Sponsors